Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease
- 1 July 1983
- journal article
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 68, 113-116
- https://doi.org/10.1111/j.1600-0404.1983.tb01524.x
Abstract
— The clinical pharmacology concerned in the evolution of deprenyl as an adjuvant in the treatment of Parkinson's disease is briefly reviewed, with an assessment of its therapeutic potential. Experiments to clarify its mode of action are described, indicating that its clinical effects do not depend upon its amphetamine metabolites.Keywords
This publication has 12 references indexed in Scilit:
- Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.Journal of Neurology, Neurosurgery & Psychiatry, 1980
- L-deprenyl treatment of on-off phenomena in Parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1978
- Recent observations on the clinical pharmacology of (-)deprenylJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1978
- DEPRENYL IN PARKINSON'S DISEASEThe Lancet, 1977
- The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenilJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1975
- Amphetamines in the treatment of Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1975
- Monoamine oxidase inhibitors and L-dopa.BMJ, 1970
- Some observations upon a new inhibitor of monoamine oxidase in brain tissueBiochemical Pharmacology, 1968
- Der L-Dioxyphenylalanin (=L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: Zur Pathogenese und Behandlung der Parkinson-AkineseArchiv Fur Psychiatrie Und Nervenkrankheiten, 1962
- Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen SystemsJournal of Molecular Medicine, 1960